Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trading float is 19M
NKTX
The huge surge in Covid in Beijing is a negative cryptocurrency catalyst.
Shares of Nkarta Inc. (NKTX) skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceutical company announced positive results from a Phase 1 trial of its cancer treatments. The rally comes after the stock closed at a record low of $7.77 on Friday. The company said its NKX101 and NKX019 co-lead candidates showed "striking single-agent activity" in a heavily pretreated patient populations, with an "exceptional safety provide" without side effects associated with CAR T cell therapies. Cowen analyst Salim Syed reiterated his buy rating and $81 stock price target, which implies TK% upside from current levels. "Investor sentiment was pretty low going into this readout," Syed wrote in a note to clients. "And of course, we still need durability data and more n, but showing these responses today, is a major plus, and street trading valuations should now move substantially higher for both programs." The stock has now lost 2.4% year to date, while the iShares Biotechnology ETF (IBB) has dropped 19.7% and the S&P 500 has declined 11.1%.
-Tomi Kilgore
(END) Dow Jones Newswires
NKTX @ 15.15 up 96 % after positive CC.
NKTX @ 15.15 up 96 % after positive CC.
Data @ CC > 8:00AM EST
NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative
NKX019 – 5 of 6 patients with relapsed / refractory NHL treated with a three-dose regimen consisting of 1B CAR NK cells per dose achieved response (83% ORR) and 3 of 6 achieved complete response (50% CR rate); responses included DLBCL
No cytokine release syndrome (CRS), neurotoxicity or graft versus host disease (GvHD) reported for either program
Higher dose regimen of 1.5 billion x 3 doses of CAR NK cells is being evaluated in both programs
Updated data will be submitted for presentation at a future medical meeting
Conference call scheduled for today, April 25 at 8:00 am ET
NKTX up 40% @ 11.11 > CC @ 8:00 AM , EST.
ARDX @ 1.10 up 47% on FDA news
Covid surge in China sending cryptocurrencies & oil sectors downwards.
AIM up 12% @ 1.15 on news
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided a summary of clinical data that support the synergistic potential of Ampligen® (rintatolimod) with checkpoint blockade therapies.
Thomas Equels, Chief Executive Officer of AIM, commented, “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions. These data have not only affirmed but significantly evolved our belief that Ampligen as a single agent therapy, as well as in combination with the latest powerful cancer therapies, has the potential to become a breakthrough therapy for some of the most difficult to treat and deadly cancers. We are going to continue working tirelessly to advance Ampligen towards approval and commercialization with the goal of bringing much needed hope to patients and solutions to treating physicians around the world.”
Ampligen is the Company’s dsRNA drug currently being developed for globally important cancers. Ampligen has shown therapeutic synergy with checkpoint inhibitors, including increasing survival rates and efficacy, in the treatment of animal tumors when used in combination with checkpoint blockade therapies. The first detection of Ampligen’s synergistic potential with checkpoint blockade therapeutics was witnessed in pre-clinical mouse models of melanoma and pancreatic cancers. Additionally, the Company now has data from two clinical studies — in advanced recurrent ovarian cancer and triple negative breast cancer — that indicate that the drug may have similar anti-tumor activity in humans.
“Working with AIM, our Pancreatic Cancer R&D team at the Buffett Cancer Center did extensive pre-clinical research demonstrating in animal models that Ampligen had a significant therapeutic benefit in treating pancreatic cancer. This March, Prof. C.H.J. van Eijck and his team at Erasmus MC published data in the journal Cancers showing Ampligen alone was associated with extended overall survival in late-stage pancreatic cancer of 19 months. Just last week, at AACR, publications of clinical data by UPMC’s Dr. Bob Edwards in advanced recurrent ovarian cancer, and Roswell’s Dr. Pawel Kalinski in both stage 4 triple negative breast cancer and stage 4 colorectal cancer, strongly supported the advance of Ampligen into human trials for patients in pancreatic and other cancers where checkpoint drugs are not effective,” stated Michael (Tony) Hollingsworth, PhD, Associate Director, Basic Research, University of Nebraska Medical Center.
“Checkpoint drugs are powerful and important therapies, but only work on ‘hot’ tumors visible to the immune system, not ‘cold’ tumors that are immune-silent. Ampligen appears, from these data, to turn cold tumors into hot tumors and create significant therapeutic potential for a successful second round of Ampligen plus checkpoint therapy for those who do not respond to checkpoint therapy alone,” added Robert Edwards, MD, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute.
“The two ongoing Roswell Park clinical trials we recently presented findings from represent milestones in our 10-year-long NIH and DoD-funded research program aiming to convert immuno-resistant ‘cold’ tumors into ‘hot’ ones that would be more sensitive to immunotherapy. Seeing both studies successfully meet their predetermined efficacy endpoint — selective increase of cytotoxic T lymphocyte markers in tumor tissues — Roswell Park plans to move forward with critical studies assessing therapeutic efficacy of the combination of a rintatolimod-based chemokine-modulating regimen with PD-1 inhibitors, cancer vaccines and/or adoptive T cell therapies in solid tumors. Observations from our preclinical studies suggest that this multipronged strategy may benefit patients with multiple solid-tumor lesions, which are difficult to target individually,” commented Pawel Kalinski, MD, PhD, Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science at, Roswell Park Comprehensive Cancer Center.
Recurrent Ovarian Cancer: ClinicalTrials.gov: NCT03734692
The investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (KEYTRUDA®) (IVP) for patients with recurrent platinum-sensitive ovarian cancer is being conducted by the University of Pittsburgh Medical Center (UPMC). The Phase 2 trial is designed to enroll up to 45 subjects using Ampligen in combination with pembrolizumab to test the combinational activity of checkpoint blockade therapy where Ampligen is administered by injection in the peritoneal cavity where the tumor is located.
The Company’s recently announced positive interim results suggesting induction of T cell activation together with clinical responses may indicate prognostic evidence of tumor environment reprogramming that we do not see with chemotherapy alone and which may extend survival. A total of 17 patients have been enrolled and 13 were evaluable for response in the ongoing Phase 2 trial. The observed clinical responses were: 2 complete responses (15.4%), 3 partial responses (23.1%), 3 stable disease (23.1%), 5 progressions (38.4%) for a clinical benefit rate (CR+PR+SD) of 61.6%. From 13 patients, 77 IP wash samples were collected at serial time points. Measurements in IP washes revealed an acute increase in granzyme B (GZMB), perforin, TNF alpha, CXCL9, CXCL10 and CXCL11 after treatment (p<0.05). Longitudinal data revealed a progressive increase in some biomarkers in the locoregional environment; CXCL9, CXCL10, CXCL11, perforin and TNF alpha were all increased from baseline levels at cycle 1 to baseline of cycle 6 (p<0.05). CXCL12 was also increased acutely after treatment (p<0.05).
The cytokine CXCL12 observed to increase acutely after treatment functions as a chemotactic for lymphocytes. The cytokines CXCL9-11 active in antitumor responses in modulation of the tumor microenvironment (TME) to favor cytotoxic T cells required for anti-tumor cell immune activity versus regulatory T cells (Tregs), which function to protect non-tumor “self” tissue. Granzymes are serine proteases released by cytoplasmic granules within cytotoxic T cells and natural killer (NK) cells. They induce programmed cell death (apoptosis) in the target cell, eliminating cells that have become cancerous. Perforin is a protein, which creates tubules in the cell membrane allowing cell lysis. Perforin is a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.
DriveMod Kit features human machine interfaces and a lighting system that communicate vehicle status, mode, battery status, route obstruction, and more.
With the swift and simple deployment that DriveMod Kit offers, manufacturers and logistics companies can begin to reap the many benefits of autonomy, such as increased productivity, improved safety, and lowered operational costs.
Yup! nice color commentary!
And DJ LeMahieu is hitting well, and playing good defense.
I watch Yankee games . Living in New York. > YES Network > Paul O'Neil and David Cone do color commentary, with Michael Kay as game play by play announcer.
LOL, probably Fauci's wife!
With 883,000 new material-handling vehicles sold each year in the U.S., DriveMod Kit creates a sizable opportunity for Cyngn to lead the rapid adoption of turnkey AV solutions for both retrofit and new vehicles.
Lior Tal, Chairman and CEO of Cyngn, stated, “We are pleased to announce this next milestone in the adoption of autonomous industrial vehicles, which comes on the heels of our recent deployment at the Las Vegas warehouse of Global Logistics and Fulfillment (‘GLF’) with whom we are thrilled to be working as their exclusive autonomous vehicle technology partner. GLF plans to expand self-driving capabilities to multiple US-based facilities, and with the development of this new fleet of Cyngn-powered Columbia Stockchasers, we look forward to helping other organizations take advantage of the benefits of autonomous vehicles.”
“Customers have been looking for ways to automate their workflows for years, and we believe that the time is right to bring self-driving capabilities to Columbia vehicles,” said Greg Breckley, Columbia’s Director of Business Development. “By launching production of our first fleet, we’re bringing the full range of Stockchaser’s well-known capabilities and pairing it with autonomous driving technology for a new era of Built for Work vehicles.”
“For us,” added Breckley, “the GLF announcement was a strong indication that our customers are hungry for autonomous vehicle technology. It is time to make this cutting-edge technology available to many more organizations.”
“Our work with Columbia Vehicle Group and GLF has paved the way for expanded deployment of our products in support of the increased demand for autonomous vehicle solutions we are seeing in industrial material handling,” added Cyngn Director of Product, Jordan Stern. “Production of this new AV fleet marks a major step forward in serving that demand. We look forward to tackling an even broader range of use cases for Columbia’s existing customers as well as the new customers we will be onboarding together.”
Cyngn’s Enterprise Autonomy Suite comprises a slate of products that includes DriveMod: Cyngn’s AI-powered AV technology stack and Cyngn Insight: software tools for data analytics, fleet management, and operational insights. EAS is a comprehensive solution that makes it easy to manage an autonomous vehicle fleet and give operators the information they need to run their organizations more efficiently.
Organizations that are interested in signing up for autonomous vehicle deployments can do so by visiting https://cyngn.com/columbia.
About Cyngn
Cyngn is an autonomous vehicle technology company that is focused on addressing industrial uses for autonomous vehicles. Cyngn believes that technological innovation is needed to enable the adoption of autonomous industrial vehicles that will address the substantial industry challenges that exist today. These challenges include labor shortages, lagging technological advancements from incumbents, and high upfront investment requirements. Cyngn addresses these challenges with its Enterprise Autonomy Suite, which includes DriveMod (modular industrial vehicle autonomous driving software), Cyngn Insight (customer-facing software suite for monitoring/managing AV fleets and aggregating/analyzing data), and Cyngn Evolve (internal toolkit that enables Cyngn to leverage data from the field for artificial intelligence, simulation, and modeling).
?To learn more, please visit https://cyngn.com/.
About Columbia Vehicle Group
Columbia Vehicle Group is an electric vehicle manufacturer whose history dates back to 1946. Based in Reedsburg, Wisconsin, Columbia manufactures vehicles built for work in industrial and commercial environments. Designed to enhance productivity, comfort and utility, Columbia vehicles optimize operational performance in transporting, carrying, and towing - all with zero emissions. To see Columbia’s full lineup of vehicles, visit www.columbiavehicles.com.
Columbia Vehicle Group is part of the Nordic Group of Companies, a family-owned management and manufacturing business headquartered in Baraboo, Wisconsin with operations extending throughout the United States, Mexico, and Europe.
Thanks! Good Barron's article !
$5.00+ this week. > 7M share trading float.
Investors are forward looking!
CYN
Investors are forward looking!
CYN
$olid day! ..... moving up in AH
CYN
Agree! Should surge past 9.91 from last October within a couple of months.
CYN
Going gangbusters into closing bell!
CYN
CYN @ 2.73
Your weclome tj1 > How about an Amazon contract to upgrade with the latest AI material handling equipment! Regardless, there are 1000's of industrial sector companies that could be on board with CYN.
2.42 > hod
CYN @ 2.42 > hod.
JCSE up 376% > Dishwasher IPO.> Who would've thunk!!!!!
Cleantech Holdings Limited Shares Open For Trade At $14.20; IPO Priced $4/Share
JCSE
JE Cleantech Holdings Limited is engaged in the sale of cleaning systems and other equipment and the provision of centralized dishwashing and ancillary services. It manufactures a range of cleaning systems, including aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment. It also provides centralized dishwashing services for the food and beverage industry, mainly for food and beverage establishments in Singapore such as food courts, hawker centers, restaurants, cookhouses, eldercare homes, and an inflight catering service provider. It also provides general cleaning services mainly for food courts in Singapore. It provides centralized dishwashing services at its Hygieia Facility in Singapore. It also provides leasing services of dishwashing equipment to its customers. The terms of the leases are typically for a period of one to two years (s) and renew automatically, and its customers are charged a fixed monthly fee for such leasing services.
CYN > 2.27
Ben Landen
VP of Business Development
Previously: Company's Senior Director of Product & Partnerships, Head of Product & BD at DeepScale (acquired by Tesla), managed $100M automotive semiconductor product line as Senior Business Manager of Maxim Integrated. MBA at UC Berkeley's Haas School of Business, and BS Electrical Engineering at California Polytechnic University SLO.
Biao Ma
VP of Engineering
Previously: Software architect for autonomous driving and senior software engineer at Baidu, software engineer at Carnegie Mellon University. MS Computer Science at Carnegie Mellon.
Lior Tal
CEO & Chairman of the Board
Previously: Director of international growth and partnerships at Facebook, co-founder and VP of business development at Snaptu (acquired by Facebook), partner at Barzam, Tal, Lerer Attorneys at Law and Patent Attorneys. Held leadership roles at Actimize (acquired by NICE), DiskSites (acquired by EMC), Odigo (acquired by Comverse).
LMAO > " there will be no genders in 50 years, " Does that go for cats, dogs, and birds too!
I posted some good info tech on the CYN board. btw, we're looking at a 7M trading float, with heavy volume.
CYN > Amazing company. If you own Tesla, you understand CYN.
CYN > back on track! > Amazing company! @ 2.19
In the field of technology, who can be more successful, a fresh investor or an experienced one? An experienced person will be more successful than an inexperienced one. One who is in the field for the last 25 years will know all the facts and figures of the relevant industry. If you’re an amateur technology investor, you’ll be aware of the name Jeff Brown. He’s one of the most experienced tech investors who has worked with different multinational companies. Over the last three years, all his predictions about technology investment have come true. If technology is about to face any challenge or change in the future, Jeff Brown recognizes that challenge or change months and years before. So, Jeff Brown investor is the most credible person in the field of technology.
Many people love to consult him as he knows the future of all the tech companies. He immediately predicts the future of a company and invests in that one to gain profit in the future. He has been successful almost in all of his investments. This is the thing that made him world-famous. He’s the king of the tech industry as he knows all the ups and downs that this industry may face in the future. His company, Brownstone Research, is working successfully in the relevant field. A single tip by him or his company can result in a big deal of profit in the near coming days.
Jeff Brown gave a heads up on this Co a couple weeks ago. props to him.